SGLT-2 inhibitors are hypothesized to enhance these effects, and careful consideration of existing evidence and physiopathological interactions across the SGLT-2 pharmacology, AF, and HF sections supports prioritizing rhythm-control strategies when initiating SGLT-2 treatment [60,71]. Here, SLC5A2 is linked to atrial fibrillation.